(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






Latest News Releases From The Newsroom

Ceragon Receives Over $60 Million in Orders for its IP-20 Platform from Tier 1 Mobile Operator in India to Support Rapid 4G Network Expansion

January 18th, 2017

Ceragon continues its role in significantly increasing 4G service coverage and network capacity Little Falls, New Jersey / CRWE PRESS RELEASE / January 18, 2017 - Ceragon Networks Ltd. (NASDAQ: CRNT), the #1 wireless backhaul specialist, toda. Read more

Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

January 17th, 2017

* PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients * This approval joins those from the U.S. FDA and U.K. fo. Read more

Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen

January 17th, 2017

* Biogen will pay Forward a non-refundable cash fee of $1.25 billion * Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain . Read more

Globus Maritime Announces Update Regarding Private Placement

January 13th, 2017

Athens, Greece / CRWE PRESS RELEASE / January 13, 2017 - Globus Maritime Limited ("Globus," or the "Company"), (NASDAQ: GLBS), a dry bulk shipping company, announced today that its previously disclosed private placement and conversion of debt will no. Read more

Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

January 12th, 2017

* Top line results from the 172-patient trial to be reported in early 2018 * Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe * 14 million people in the U.S. are treate. Read more

Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR as its Mutation Enrichment Platform

January 12th, 2017

Three-Year Renewable Agreement Also Includes Non-Exclusive License to ICP in Canada New Patent Has Issued Covering ICE COLD-PCR Technology in Canada OMAHA, Neb. / CRWE PRESS RELEASE / January 12, 2017 - Transgenomic, Inc. (TBIO) (NASDAQ: . Read more

NOVADAQ Announces Preliminary Unaudited Fourth Quarter 2016 Revenue and Issues 2017 Revenue Guidance

January 11th, 2017

Secures up to $60 million in financing from Midcap Financial Toronto, Ontario / CRWE PRESS RELEASE / January 10, 2017 - NOVADAQ Technologies Inc (NASDAQ:NVDQ; TSX:NDQ), the leading provider of proven comprehensive fluorescence . Read more

GM Expects Earnings Growth Again in 2017; Increases Stock Repurchase Program

January 10th, 2017

* Announces 2017 EPS diluted-adjusted outlook of $6.00-$6.50 * Expects to maintain or improve EBIT-adjusted and EBIT-adjusted margin * Authorizes additional $5 billion for share repurchases * Increases cost efficiency target to $6.5 billion throug. Read more

Taseko Announces Record Quarterly Copper and Molybdenum Production at Gibraltar

January 09th, 2017

Vancouver, BC / CRWE PRESS RELEASE / January 9, 2017 - Taseko Mines Limited (TSX: TKO; NYSE MKT: TGB) (“Taseko” or the “Company”) is pleased to announce fourth quarter copper production of 40.7 million pounds and 0.8 million p. Read more

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

January 09th, 2017

WALTHAM, Mass. / CRWE PRESS RELEASE / January 9, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing pro. Read more